BCN 303
Alternative Names: BCN-303Latest Information Update: 01 Apr 2021
At a glance
- Originator BCN Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer
Most Recent Events
- 03 Mar 2021 Preclinical trials in Breast cancer in USA (Parenteral) (BCN Biosciences pipeline, March 2021)
- 03 Mar 2021 Preclinical trials in Colorectal cancer in USA (Parenteral) (BCN Biosciences pipeline, March 2021)